Coloplast announced it will acquire wound care product company Kerecis for $1.3 billion. The acquisition will give Coloplast an opportunity to “strategically strengthen [its] presence in the advanced ...

Coloplast A/S is acquiring Kerecis hf, a closely held Icelandic maker of fish-skin dressings to treat human wounds, for an enterprise value of up to $1.3 billion.

Coloplast has offered up 8.9 billion Danish kroner, or around $1.3 billion, in the deal. The vast majority—8.2 billion kroner ($1.2 billion)—will be doled out as an upfront cash payment.

Coloplast, a leading company within intimate healthcare, will invest around 100 million euros in a new manufacturing site in Portugal to support the company’ s continued growth.. With the new ...

Coloplast has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up to $1.3 billion, the Danish medical equipment maker ...

Coloplast’s recent price decline can be traced to a dramatic drop in its cash return on invested capital (CROIC), plunging from a spectacular 45.3% in 2020 to a rather deflated 4.1% in 2024, ...

Coloplast's ownership structure favors the holders of A shares (mainly the Louis-Hansen founding family), which holds 44% of the equity but retains 68% of the voting power.

Coloplast's woundcare portfolio is relatively limited, especially when compared with the breadth of products from Smith & Nephew, and Convatec, which include high-tech solutions such as negative ...